Patents by Inventor Richard M. Lawn

Richard M. Lawn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INCREASING CHOLESTEROL EFFLUX AND RAISING HDL USING ATP BINDING CASSETTE TRANSPORTER PROTEIN ABC1
    Publication number: 20080227099
    Abstract: The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.
    Type: Application
    Filed: February 25, 2008
    Publication date: September 18, 2008
    Inventors: Richard M. Lawn, David Wade, Michael Garvin
  • Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter protein ABC1
    Patent number: 7351535
    Abstract: The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: April 1, 2008
    Assignee: CV Therapeutics, Inc.
    Inventors: Richard M Lawn, David Wade, Michael Garvin
  • Methods and Deoxyribonucleic acid for the preparation of tissue factor protein
    Patent number: 7084251
    Abstract: DNA isolates coding for tissue factor protein and methods of obtaining such DNA and producing tissue factor protein using recombinant expression systems for use in therapeutic composition for the treatment of coagulation disorders.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: August 1, 2006
    Assignee: Genentech, Inc.
    Inventors: Richard M. Lawn, Gordon A. Vehar, Karen L. Wion
  • Methods and deoxyribonucleic acid for the preparation of tissue factor protein
    Patent number: 7049131
    Abstract: DNA isolates coding for tissue factor protein and methods of obtaining such DNA and producing tissue factor protein using recombinant expression systems for use in therapeutic composition for the treatment of coagulation disorders.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: May 23, 2006
    Assignee: Genentech, Inc.
    Inventors: Richard M. Lawn, Gordon A. Vehar, Karen L. Wion
  • Methods and deoxyribonucleic acid for the preparation of tissue factor protein
    Patent number: 6994988
    Abstract: DNA isolates coding for tissue factor protein and methods of obtaining such DNA and producing tissue factor protein using recombinant expression systems for use in therapeutic composition for the treatment of coagulation disorders.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 7, 2006
    Assignee: Genetech, Inc.
    Inventors: Richard M. Lawn, Gordon A. Vehar, Karen L. Wion
  • Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
    Patent number: 6835563
    Abstract: The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: December 28, 2004
    Assignee: CV Therapeutics
    Inventors: Richard M. Lawn, David Wade, Michael Garvin, John F. Oram
  • Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
    Patent number: 6821774
    Abstract: The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: November 23, 2004
    Assignee: CV Therapeutics, Inc.
    Inventors: Richard M. Lawn, David Wade, Michael Garvin
  • Vectors and cell lines capable of correctly splicing exon regions
    Patent number: 5683905
    Abstract: A recombinant DNA vector is provided that expresses exons of genomic DNA fragments that are inserted into the vector. The vector contains a promoter and a genomic DNA fragment so characterized and configured that the vector, upon transcription in a transfected eukaryotic cell culture, expresses the corresponding RNA segment of the genomic DNA fragment free of any intron.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: November 4, 1997
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Capon, Richard M. Lawn, Gordon A. Vehar, William I. Wood
  • Preparation of functional human factor VIII and pharmaceutical treatment therewith
    Patent number: 5668108
    Abstract: Functional human factor VIII produced recombinantly is used in the treatment of human beings diagnosed to be deficient in factor VIII coagulant activity. Also provided are DNA isolates and expression vehicles encoding functional human factor VIII, as well as transformed host cells and processes for producing human factor VIII by use of recombinant DNA technology.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: September 16, 1997
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Capon, Richard M. Lawn, Gordon A. Vehar, William I. Wood
  • Preparation of functional human factor VIII
    Patent number: 5633150
    Abstract: Functional human factor VIII produced recombinantly is used in the treatment of human beings diagnosed to be deficient in factor VIII coagulant activity. Also provided are DNA isolates and expression vehicles encoding functional human factor VIII, as well as transformed host cells and processes for producing human factor VIII by use of recombinant DNA technology.
    Type: Grant
    Filed: October 9, 1990
    Date of Patent: May 27, 1997
    Assignee: Genentech, Inc.
    Inventors: William I. Wood, Daniel J. Capon, Richard M. Lawn, Gordon A. Vehar
  • Preparation of functional human factor VIII and pharmaceutical treatment therewith
    Patent number: 5618788
    Abstract: Functional human factor VIII produced recombinantly is used in the treatment of human beings diagnosed to be deficient in factor VIII coagulant activity. Also provided are DNA isolates and expression vehicles encoding functional human factor VIII, as well as transformed host cells and processes for producing human factor VIII by use of recombinant DNA technology.
    Type: Grant
    Filed: August 20, 1990
    Date of Patent: April 8, 1997
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Capon, Richard M. Lawn, Gordon A. Vehar, William I. Wood
  • Functional human factor VIII
    Patent number: 5618789
    Abstract: Functional human factor VIII produced recombinantly is used in the treatment of human beings diagnosed to be deficient in factor VIII coagulant activity. Also provided are DNA isolates and expression vehicles encoding functional human factor VIII, as well as transformed host cells and processes for producing human factor VIII by use of recombinant DNA technology.
    Type: Grant
    Filed: February 3, 1992
    Date of Patent: April 8, 1997
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Capon, Richard M. Lawn, Gordon A. Vehar, William I. Wood
  • Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
    Patent number: 5049488
    Abstract: Nucleic acid encoding lecithin:cholesterol acyltransferase is ligated into expression vectors and used to transform host cells for the synthesis of lecithin:cholesterol acyltransferase in recombinant cell culture. Lecithin:cholesterol acyltransferase amino acid sequence variants are described for enhancing the properties of lecithin:cholesterol acyltransferase. Lecithin:cholesterol acyltransferase and its variants are employed in the therapy of conditions characterized by hypercholesterolemia and for the mobilization of cholesterol in vivo.
    Type: Grant
    Filed: November 8, 1985
    Date of Patent: September 17, 1991
    Assignee: Genentech, Inc.
    Inventors: Bradford W. Baer, Dennis T. Drayna, Richard M. Lawn, John W. McLean
  • Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
    Patent number: 4965199
    Abstract: A method for producing factor VIII in recombinant mammalian host cells utilizing an expression vector containing a selectable marker DNA and an amplifiable marker DNA. The initial selection is based upon the selectable marker and subsequent amplification of factor VIII DNA and amplifiable marker DNA is conducted in cells not deficient in the amplifiable marker.
    Type: Grant
    Filed: August 7, 1987
    Date of Patent: October 23, 1990
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Capon, Richard M. Lawn, Arthur D. Levinson, Gordon A. Vehar, William I. Wood
  • Human antithrombin III
    Patent number: 4632981
    Abstract: Human antithrombin III (AT III) as a product of genetically altered cell culture.
    Type: Grant
    Filed: February 1, 1985
    Date of Patent: December 30, 1986
    Assignee: Genentech, Inc.
    Inventors: Susan C. Bock, Richard M. Lawn
  • Human antithrombin III
    Patent number: 4517294
    Abstract: A DNA sequence encoding human antithrombin III, cloning vehicles and cells containing that DNA sequence.
    Type: Grant
    Filed: July 30, 1982
    Date of Patent: May 14, 1985
    Assignee: Genentech, Inc.
    Inventors: Susan C. Bock, Richard M. Lawn